FCM
STRO icon

Farallon Capital Management’s Sutro Biopharma STRO Stock Holding History

Farallon Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,000
Closed -$2.25M – 103
2018
Q3 		$2.25M Buy
+15,000
New +$2.27M 0.01% 100

Other funds holding STRO

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Farallon Capital Management's STRO Position: Q4 2018 in Review

Farallon Capital Management sold out of Sutro Biopharma (STRO) in Q4 2018, closing a stake of 15,000 shares — an estimated $2.25M sold.

Farallon Capital Management first reported a position in STRO in Q3 2018 and held it in 1 quarter. The position peaked at $2.25M in Q3 2018. 43 funds tracked by Wall St. Rank hold STRO as of Q4 2018.

  • Farallon Capital Management reported no remaining Sutro Biopharma position as of Q4 2018 after selling out during the quarter.
  • Farallon Capital Management sold 15,000 Sutro Biopharma shares in Q4 2018, an estimated $2.25M.
  • Farallon Capital Management first reported a position in Sutro Biopharma in Q3 2018 and held it in 1 quarter.
  • Farallon Capital Management's Sutro Biopharma position peaked at $2.25M in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2018.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.